Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Carter Worth, Worth Charting, talks technicals on Morgan Stanley and Novo Nordisk. Trump Signs Executive Order To Change College Accreditation What is the most American-made car? Trump Shoots Down ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.

MONDAY, April 21, 2025 (HealthDay News) -- The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic ...

Ifølge Eli Lilly er pillen den første af sin slags, som kommer succesfuldt gennem et fase 3-studie. Novo Nordisk har tidligere testet et middel i pilleform, som var målrettet vægttab. Resultaterne af ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer ...

Unfortunately, what's good news for Eli Lilly is probably bad news for investors in Novo Nordisk and Viking Therapeutics, both of which lag Lilly in the race to develop their own easy-to-take GLP ...